Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.3% in the fourth quarter, HoldingsChannel reports. The firm owned 118 shares of the biopharmaceutical company’s stock after selling 49 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Regeneron Pharmaceuticals were worth $84,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Douglass Winthrop Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 70.1% during the 4th quarter. Douglass Winthrop Advisors LLC now owns 364 shares of the biopharmaceutical company’s stock valued at $259,000 after purchasing an additional 150 shares during the period. Whittier Trust Co. raised its position in shares of Regeneron Pharmaceuticals by 12.8% during the 4th quarter. Whittier Trust Co. now owns 863 shares of the biopharmaceutical company’s stock worth $615,000 after buying an additional 98 shares in the last quarter. Blueshift Asset Management LLC raised its position in shares of Regeneron Pharmaceuticals by 284.4% during the 4th quarter. Blueshift Asset Management LLC now owns 1,303 shares of the biopharmaceutical company’s stock worth $928,000 after buying an additional 964 shares in the last quarter. Magnetar Financial LLC raised its position in shares of Regeneron Pharmaceuticals by 1,445.0% during the 4th quarter. Magnetar Financial LLC now owns 108,150 shares of the biopharmaceutical company’s stock worth $77,038,000 after buying an additional 101,150 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its position in shares of Regeneron Pharmaceuticals by 32.5% during the 4th quarter. Teacher Retirement System of Texas now owns 38,932 shares of the biopharmaceutical company’s stock worth $27,732,000 after buying an additional 9,554 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on REGN. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Bank of America restated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $658.48 on Monday. The company’s 50 day moving average price is $689.43 and its 200 day moving average price is $813.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a market capitalization of $71.99 billion, a PE ratio of 17.20, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.